NanoSphere Health Sciences, Inc.
CCSE:NSHS.X0.02
CAD
0.00
(0.00%)
ISIN
CA63010P2098
CUSIP
63010P209
Return %
Stock
S&P 500
1Y
-33.33
14.20
3Y
33.33
81.12
5Y
-94.29
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Vancouver Canada
- IPO Date
- Aug 11, 2005
- Website
- nanospherehealth.com
- Similar Companies
- Business
- NanoSphere Health Sciences, Inc. is a biotechnology company specializing in the development, patenting, and commercialization of advanced lipid nanoparticle drug delivery platforms for the pharmaceutical, nutraceutical, cannabinoid, and animal health industries. The company's core product and technology portfolio comprises the patented NanoSphere Delivery System, a proprietary nanotechnology platform designed to encapsulate active biological compounds into protective lipid membranes to enhance bioavailability, accelerate onset of action, and bypass gastrointestinal degradation; the Evolve Formulas brand, featuring cannabis-derived formulations such as Transdermal NanoSerum for direct cutaneous application and systemic absorption; precision-metered intra-oral and sublingual liquid delivery systems; intranasal administration formulations for targeted delivery; nonsteroidal anti-inflammatory drug and over-the-counter analgesic delivery applications; dietary supplement and nutraceutical encapsulation solutions; and intellectual property licensing, contract research, and commercialization agreements for third-party manufacturers. Founded in 2005 and headquartered in Vancouver, British Columbia, Canada, with operational facilities in Greenwood Village, Colorado, the company operates through its primary subsidiary, NanoSphere Health Sciences, LLC, serving medical, recreational, wellness, and veterinary markets primarily in North America. In recent developments, the Canadian Securities Exchange designated the company as an inactive issuer, updating its trading symbol from NSHS to NSHS.X due to non-compliance with continued listing requirements, which subjects the enterprise to exchange approval requirements for future financings as it evaluates corporate restructuring and strategic opportunities for its delivery technologies.